SUN bioscience is a biotechnology company specializing in personalized medicine through its proprietary high-throughput 3D microwell platform for organoid culture. The company develops standardized and reproducible organoids derived from patient stem cells to enable efficient drug testing and development. Its flagship technology, Gri3D®, addresses challenges in organoid culture such as automation, scalability, robustness, and imaging, facilitating new advances in drug development and clinical diagnostics. SUN bioscience's organoid models include retinal, intestinal, cerebral, pancreatic, otic, and liver tissues, serving academic and corporate clients globally. The company aims to make organoid technologies an industry standard to revolutionize precision healthcare and improve treatment efficacy for patients. SUN bioscience was founded by researchers with extensive experience in stem cell-derived in vitro models and is recognized for its innovation in the biotech sector.